DHDavid Hernández-Barajas

David Hernández-Barajas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Hernández-Barajas has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Carlos Eduardo Salazar-Mejía

    Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    4 shared publications
  • Edio Llerena-Hernández

    Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    3 shared publications
  • Adriana González-Gutiérrez

    Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    2 shared publications
  • Blanca Otilia Wimer-Castillo

    Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    2 shared publications
  • José Luis González-Vela

    Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    2 shared publications
  • María Inés Contreras-Salcido

    Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    2 shared publications

Latest Publications

  • Open Access

    Delayed hypersensitivity reactions to taxanes: Clinical presentation and outcomes of post-medication and rapid drug desensitization

    by Rosalaura Villarreal-González, Leslie Astrid De la Fuente, Alexia Moreno-Silvestre, María Guadalupe Durán-Hernández, Diego Armando Sánchez-Alvarado, David Hernández-Barajas, Oscar Vidal-Gutiérrez


  • Open Access

    Nutritional screening in oncologic patients taking chemotherapy in a reference cancer center

    by Y. De Zamacona, O.A. Zayas, J.M. Martinez, A. Saenz, D. Hernandez Barajas, O. Vidal Gutierrez

  • Open Access

    Desnutrición en pacientes recién diagnosticadas con cáncer ginecológico.

    by Marisol Brito Alvarez, David Hernández Barajas, Silvia Elvira Tavitas Herrera, Gustavo Israel Martínez González, María Luisa Romero Lagunes

    Introducción: La incidencia y prevalencia del cáncer ginecológico en nuestro país continúa creciendo y con ello la desnutrición y sus complicaciones, la valoración global subjetiva generada por el paciente (VGS-GP) identifica a los pacientes en riesgo de desnutrición/desnutrición moderada y desnutrición (Categoría B/C) que necesitan intervención nutricional. Objetivo: Determinar la desnutrición que presentan las pacientes recién diagnosticadas con cáncer ginecológico. Material y Método: Estudio transversal, exploratorio, descriptivo, correlacional que incluyó 64 pacientes >20 años recién diagnosticadas con cáncer cervicouterino (CaCU), endometrio (CaE), ovario (CaO) y vulvar (CaV), sin tratamiento. Evaluamos VGS-GP, albúmina, % pérdida de peso (%PP). Los datos recopilaron en Excel 2011 y se analizaron en IBM Stadistics 23. Resultados: La VGS-GP reportó 25% de los pacientes en (Categoría B) y 29.7% (Categoría C). El IMC identificó con desnutrición a 6.3%. El %PP en 1 y 6 meses fue mayor en la Categoría B/C (p 0.000), la VGS-GP en categoría B y C presento mayor correlación con incremento de %PP, albumina disminuida y sintomatología en el paciente oncológico. Conclusión: La VGS-GP reportó 29.7% en desnutrición mientras el IMC el 6.3%, esta herramienta identifica a pacientes con cáncer ginecológico en riesgo de desnutrición y/o desnutrición (54.68%) que requieren intervención nutricional.

  • Open Access

    VULVAR CANCER: 20 YEAR OF EXPERIENCE FROM A REFERRAL CENTER IN MEXICO.

    by Yuridia Evangelina, Abraham Guerra, David Hernández, Óscar Vidal

    Introduction/Background Vulvar cancer is one of the less frequent gynecological tumors, with only 4% occurrence in patients, with a mean age at diagnosis of 68 years. In Mexico, it represents 0.22% of all tumors, however, its incidence in the last few years has been rising in hand with human papillomavirus infection and smoking. The most common symptoms are pruritus, ulcers,

  • Open Access

    Accuracy of clinical staging for rectal cancer

    by J. Hernández Benitez, K. Camacho Elizondo, C. de la Cruz de la Cruz, D. Gallegos Arguijo, D. Ruiz Sánchez, D. Hernández Barajas

    Introduction: Treatment of rectal cancer depends on stage. Nonmetastatic locally advanced tumors should receive neoadjuvant therapy. Magnetic resonance imaging (MRI) is recommended for preoperative staging. However, MRI is not available in several regions of low and middle-income countries. Even if available, many patients cannot afford it and some clinicians choose to define treatment based only on a computed tomography (CT), especially if this suggests very locally advanced disease.


  • Open Access

    Cardiac Tamponade as an Initial Manifestation of Cervical Cancer

    by Yuridia Evangelina Rodríguez-Rosales, Carlos Eduardo Salazar-Mejía, Blanca Angélica Soto-Martínez, David Hernández-Barajas, Oscar Vidal-Gutiérrez, Gabriela Sofia Gómez-Macías

    Cervical cancer is the second most common malignancy worldwide in women and the third most common cause of cancer death in developing countries. This type of cancer spreads mainly to the lung, the bone, and the brain; however, the pericardium is an unusual site of invasion, which is associated with a poor prognosis. We present a case of a 35-year-old woman with six months of leg edema and abnormal uterine bleeding. During the initial evaluation, cardiac tamponade and a bilateral pleural effusion were found. A left supraclavicular lymphadenopathy was identified on physical examination, while gynecological examination and MRI were irrelevant. Initial cytology of the pericardial fluid showed a poorly differentiated carcinoma, and a cervical biopsy revealed a squamous cell invasive carcinoma. Chemotherapy was started with carboplatin and paclitaxel, but no clinical improvement was noted and the patient died 46 days after arrival. Cardiac tamponade in a young female patient is a harbinger to widen the differential diagnosis to include not only infectious, cardiac, or metabolic etiology but also oncological causes since this will allow appropriate treatment.


  • Open Access

    Choriocarcinoma Syndrome as an Initial Presentation of Testicular Cancer

    by Carlos Eduardo Salazar-Mejía, María Elena García-Gutiérrez, María Inés Contreras-Salcido, Carlos Javier Rodríguez-Álvarez, Blanca Otilia Wimer-Castillo, Jackeline Grace Lara-Campos, Edio Llerena-Hernández, José Luis González-Vela, David Hernández-Barajas

    Choriocarcinoma syndrome (CS) is a rare clinical entity within the spectrum of nonseminomatous germ-cell tumors (NSGCT). It is characterized by the abrupt establishment of rapidly progressive and hemorrhagic tumors associated with very high levels of the beta fraction of human chorionic gonadotropin (β-hCG) and with a very poor prognosis, particularly in patients with β-hCG values above 50,000 IU/L. We present the case of a 17-year-old man with a sudden onset nonmassive hemoptysis. Physical examination revealed a right testicular mass. Imaging studies showed metastatic lung, bone, and retroperitoneal disease. β-hCG serum levels were 222,493.21 IU/L, AFP 1.56 ng/mL, and DHL 457 IU/L. Histopathological study after right radical orchiectomy showed a mixed germ-cell tumor. Based on poor-risk characteristics, chemotherapy was started with an adequate clinical response. Physicians should be aware of the potential complications of CS in the treatment of testicular cancer with high β-hCG levels since they could be associated with a rapidly progressive and high-volume disease. Patients in this category should be referred to the centers experienced in the treatment of advanced germ-cell tumors. Due to the severity of the presentation, hemodynamic monitoring, ideally in an intensive care unit, is essential as well as timely administration of cytotoxic treatment.


  • Open Access

    Malignant Spinal Cord Compression Syndrome as an Initial Presentation of Testicular Cancer

    by Carlos Eduardo Salazar-Mejía, Edio Llerena-Hernández, David Hernández-Barajas, Oscar Vidal-Gutiérrez, Adriana González-Gutiérrez, Rolando Jacob Martínez-Granados, Blanca Otilia Wimer-Castillo

    Malignant spinal cord compression syndrome (MSCCS) occurs in 2.5 to 5% of all oncological patients. In 20% of the cases, it is the initial manifestation. This syndrome is a rare event among germ cell tumors (GCT), occurring in only 1.7% of the patients. We present the case of a 24-year-old man who arrived at the emergency department with dysesthesia and paraparesis as well as urinary incontinence. Imaging studies showed an infiltrative lesion in the left testicle, pulmonary and hepatic metastatic disease, and a large retroperitoneal ganglionar conglomerate that infiltrated the spinal cord through the intervertebral foramina of the vertebra level T11 with displacement of the L1 vertebral body. A postoperative biopsy showed a pure embryonal carcinoma. In the initial approach of a young man who presents spinal cord compression, the presence of MSCCS associated with GCT should be considered as a possible cause. A high level of suspicion is required to achieve a timely diagnosis, to grant the patient the best possible outcome.


  • Open Access

    Testicular Cancer Presenting as Gastric Variceal Hemorrhage

    by Carlos Eduardo Salazar-Mejía, David Hernández-Barajas, Edio Llerena-Hernández, José Luis González-Vela, María Inés Contreras-Salcido, Adriana González-Gutiérrez, Omar David Borjas-Almaguer, Luis Alberto Pérez-Arredondo, Blanca Otilia Wimer-Castillo

    Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35. The symptomatology caused by this tumor varies according to the site of metastasis. We present the case of a 26-year-old male who arrived to the emergency department with hematemesis. He had no previous medical history. On arrival, we noted enlargement of the left scrotal sac. There was also a mass in the left scrotum which provoked displacement of the penis and right testis. The serum alpha-fetoprotein level was 17,090 ng/mL, lactate dehydrogenase was 1480 U/L, and human chorionic gonadotropin was 287.4 IU/mL. Upper endoscopy revealed a type 1 isolated gastric varix, treated with cyanoacrylate. A CT scan showed extrinsic compression of the portal vein by lymphadenopathy along with splenic vein partial thrombosis, which caused left-sided portal hypertension. Neoadjuvant chemotherapy was started with etoposide and cisplatin, and seven days later the patient underwent left radical orchiectomy. A postoperative biopsy revealed a pure testicular teratoma. Noncirrhotic left portal hypertension with bleeding from an isolated gastric varix secondary to metastasic testicular cancer has not been described before. Clinicians must consider the possibility of malignancy in the differential diagnosis of a young man presenting with unexplained gastrointestinal bleeding.